文献速递肝病

荟萃分析:接受生物制剂治疗患者的乙型肝炎再激活

Meta-analysis: hepatitis B reactivation in patients receiving biological therapy.
PubMed 文献 · Aliment Pharmacol Ther · 2022-08-17

该荟萃分析遵循MOOSE指南系统检索EMBASE、MEDLINE和PubMed,纳入29项研究共1409例HBV感染患者,评估TNFα抑制剂、乌司奴单抗和维得利珠单抗的HBV再激活(HBVr)患病率。结果显示慢性携带者与隐匿性携带者的HBVr患病率不同,高危组抗病毒预防用药率低,与临床实践指南相悖。

要点

  • 慢性HBV携带者中,英夫利西单抗的HBVr患病率为40.5%(95%CI 20.3-64.5%,n=4)。
  • 隐匿性HBV感染者中,乌司奴单抗的HBVr患病率为6.4%(95%CI 2.2-16.8%,n=5)。
  • 慢性HBVr组24例患者中仅3例接受抗病毒预防,高危组预防用药率低。

核心结论

  • 慢性携带状态与隐匿性携带状态的HBVr患病率不同。
  • 高危组抗病毒预防治疗的采用率低,与临床实践指南相悖。

研究设计与样本

  • 遵循MOOSE指南进行系统文献检索,检索EMBASE(Ovid)、MEDLINE(Ovid)和PubMed。
  • 纳入29项研究,共1409例HBV感染患者,包括慢性与隐匿性HBV携带者,涵盖风湿性、皮肤性或胃肠性疾病。
  • 采用随机效应模型计算合并估计值(HBVr患病率及95%置信区间)。

主要发现

  • 慢性HBV携带者中,阿达木单抗的HBVr患病率为17.1%(95%CI 7.0-35.9,n=5)。
  • 慢性HBV携带者中,依那西普的HBVr患病率为16.6%(95%CI 9.5-27.5%,n=6)。
  • 慢性HBV携带者中,英夫利西单抗的HBVr患病率为40.5%(95%CI 20.3-64.5%,n=4)。
  • 慢性HBV携带者中,乌司奴单抗的HBVr患病率为19.1%(95%CI 7.3-41.2%,n=2)。
  • 隐匿性HBV感染者中,阿达木单抗、依那西普、英夫利西单抗和乌司奴单抗的HBVr患病率分别为5.0%(95%CI 2.8-8.7%,n=18)、2.6%(95%CI 1.4-4.7%,n=18)、4.4%(95%CI 2.2-8.7%,n=12)和6.4%(95%CI 2.2-16.8,n=5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of biologics poses a moderate to high risk for hepatitis B virus reactivation (HBVr) in chronic carriers. AIM: To determine the prevalence of HBVr with TNF alpha inhibitors, ustekinumab and vedolizumab METHOD: We followed the MOOSE guidelines and conducted a comprehensive literature search. We conducted a systematic search of EMBASE (Ovid), MEDLINE (Ovid) and PubMed. The studies included patients who were chronic and occult HBV carriers with various rheumatological, dermatological or gastroenterological conditions. We used a random effects model using pooled estimates (prevalence of HBVr with 95% confidence intervals (CI)). RESULTS: We included 29 studies with 1409 patients infected with HBV. The prevalence of HBVr in chronic carriers of HBV was 17.1% (95% CI: 7.0-35.9, n = 5), 16.6% (95% CI: 9.5-27.5%, n = 6), 40.5% (95% CI: 20.3-64.5%, n = 4) and 19.1% (95% CI: 7.3-41.2%, n = 2), respectively, for adalimumab, etanercept, infliximab and ustekinumab. The respective prevalence for reactivation in patients with occult HBV infection was 5.0% (95% CI: 2.8-8.7%, number of studies: n = 18), 2.6% (95% CI: 1.4-4.7%, n = 18), 4.4% (95% CI: 2.2-8.7%, n = 12) and 6.4% (95% CI: 2.2-16.8, n = 5). There were 39 HBVr (26 in chronic HBV and 13 in the occult group) without any hepatic failure or death. In the chronic HBVr group, only three of 24 patients received antiviral prophylaxis. CONCLUSIONS: HBVr prevalence rates differ between the chronic carrier state and the occult carrier state. The uptake of prophylactic antiviral therapy in high-risk groups was low, contrary to clinical practice guidelines.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. El Jamaly H, Eslick GD, Weltman M, et al. Meta-analysis: hepatitis B reactivation in patients receiving biological therapy. Aliment Pharmacol Ther. 2022. PMID: 35975904. doi:10.1111/apt.17155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。